Background: To compare the treatment effectiveness and safety among transarterial infusion chemotherapy (TAI) with FOLFOX regimen, transarterial chemoembolization (TACE), and sorafenib in patients with BCLC stage C hepatocellular carcinoma (HCC).
Methods: The data of consecutive patients with BCLC stage C HCC treated with TAI, TACE, or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed. Propensity-score matched (PSM) analysis was pairwise performed to reduce selection bias. Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method, log-rank test, Cox regression models, and χ test.
Results: The median overall survival (OS) in the matched TAI cohort was significantly longer than the sorafenib cohort (19.6 7.5 months, P=0.009), and the TACE cohort (estimated 27.8 6.6 months, P<0.001). The difference in median progression-free survival (PFS) between the matched TAI and sorafenib cohorts was not significant (5.8 . 2.3 months, P=0.219). The median PFS in the matched TAI cohort was significantly longer than the TACE cohort (6.5 . 2.8 months, P<0.001). The objective response rate (ORR) in the matched TAI cohort was significantly higher than the sorafenib cohort (36.4% . 0.0%, P<0.001) and the TACE cohort (48.7% . 4.7%, P<0.001). The incidences of adverse events (AEs) were similar among these three cohorts.
Conclusions: TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527433 | PMC |
| http://dx.doi.org/10.21037/hbsn.2020.03.14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma.
Front Immunol
January 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Background: The combination of local therapy with lenvatinib and programmed cell death protein-1 (PD-1) inhibitors represents an emerging treatment paradigm for unresectable hepatocellular carcinoma (uHCC). Our study sought to investigate the interrelationship between gut microbiota and intratumoral microbiota in the context of triple therapy, with a view to identifying potential biological markers.
Methods: The gut microbial community profiles of patients with primary untreated hepatocellular carcinoma (HCC) and those treated with local therapy combined with lenvatinib and PD-1 inhibitors were analyzed by 16S rRNA gene amplicon sequencing.
Comparing the performance of ChatGPT and ERNIE Bot in answering questions regarding liver cancer interventional radiology in Chinese and English contexts: A comparative study.
Digit Health
January 2025
Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Introduction: This study aims to critically assess the appropriateness and limitations of two prominent large language models (LLMs), enhanced representation through knowledge integration (ERNIE Bot) and chat generative pre-trained transformer (ChatGPT), in answering questions about liver cancer interventional radiology. Through a comparative analysis, the performance of these models will be evaluated based on their responses to questions about transarterial chemoembolization and hepatic arterial infusion chemotherapy in both English and Chinese contexts.
Methods: A total of 38 questions were developed to cover a range of topics related to transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC), including foundational knowledge, patient education, and treatment and care.
Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors.
BMC Gastroenterol
January 2025
Department of Interventional Radiology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Nangang District, Harbin, Heilongjiang Province, 150081, China.
Objective: To develop and validate a computed tomography (CT)-based deep learning radiomics model to predict treatment response and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) treated with transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors and tyrosine kinase inhibitors (TKIs).
Methods: This retrospective study included 172 patients with uHCC who underwent combination therapy of TACE-HAIC with TKIs and PD-1 inhibitors. Among them, 122 were from the Interventional Department of the Harbin Medical University Cancer Hospital, with 92 randomly assigned to the training cohort and 30 cases randomly assigned to the testing cohort.
Advanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way?
World J Gastrointest Oncol
January 2025
Department of General and Pediatric Surgery, Bolzano Central Hospital - SABES, Bolzano 39100, Trentino-Alto Adige, Italy.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with advanced stages posing significant treatment challenges. Although hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising modality for treating advanced HCC, particularly in Asian clinical practice, its adoption in Western medicine remains limited due to a lack of large-scale randomized controlled trials. This editorial reviews and comments on the meta-analysis conducted by Zhou , which evaluates the efficacy and safety of HAIC and its combination strategies for advanced HCC.
View Article and Find Full Text PDFEfficacy and safety of atezolizumab combined with bevacizumab, arterial chemoembolization, and hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma: a meta-analysis.
Int J Clin Exp Pathol
December 2024
Department of Cardiology, Affiliated Hospital Chengdu University Chengdu 610000, Sichuan, China.
Objective: Although the combination of atezolizumab and bevacizumab (A+B) shows promise for advanced hepatocellular carcinoma (HCC), its response rate is still inadequate. Previous studies indicate that the integration of FOLFOX-based hepatic arterial infusion chemotherapy (HAIC) with transarterial chemoembolization (TACE) is advantageous for the management of HCC. This meta-analysis aims to assess the safety and efficacy of the A+B+TACE or HAIC therapy protocol in patients with advanced HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!